Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  OTC Bulletin Board  >  IntelGenx Technologies Corp.    IGX

 SummaryNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Financials ($)
Sales 2017 6,57 M
EBIT 2017 -0,98 M
Net income 2017 -1,36 M
Debt 2017 -
Yield 2017 -
Sales 2018 7,08 M
EBIT 2018 -3,01 M
Net income 2018 -3,32 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 6,85x
Capi. / Sales2018 6,35x
Capitalization 45,0 M
More Financials
Company
IntelGenx Technologies Corp. operates as a drug delivery company.It focuses on the development of novel, orally administered drug delivery products based on its proprietary oral drug delivery technologies.The company is a provider of product development services for the pharmaceutical industry,... 
Sector
Pharmaceuticals
Calendar
-
More about the company
Surperformance© ratings of IntelGenx Technologies Cor
Trading Rating : - Investor Rating :
More Ratings
Latest news on INTELGENX TECHNOLOGIES COR
02:01p INTELGENX TECHNOLOGIES : Receives Health Canada Clearance to Begin Phase 2a Stud..
02:00p INTELGENX TECHNOLOGIES : Receives Health Canada Clearance to Begin Phase 2a Stud..
12/13 INTELGENX TECHNOLOGIES : Receives USPTO Notice of Allowance for Montelukast Oran..
12/11 INTELGENX TECHNOLOGIES : Receives USPTO Notice of Allowance for Montelukast Oran..
12/11 INTELGENX TECHNOLOGIES : Receives USPTO Notice of Allowance for Montelukast Oran..
12/07 INTELGENX TECHNOLOGIES : RedHill Biopharma Provides 2017 Year-End Business Updat..
12/07 INTELGENX TECHNOLOGIES : to Regain Exclusive Worldwide Rights to Develop and Com..
12/06 INTELGENX TECHNOLOGIES CORP. : Termination of a Material Definitive Agreement, O..
12/05 INTELGENX TECHNOLOGIES : IIROC Trading Resumption - IGX; IGX.DB
12/05 IIROC Trade Resumption - IntelGenx Technologies Corp.
More news
Sector news : Generic Pharmaceuticals
11:22a Germany's Merck in fresh bid to enter U.S. MS pill market
08:48aDJTEVA PHARMACEUTICAL INDUSTRIES : Generics Giant Cuts Staff by 25% -- WSJ
07:34aDJNOVARTIS : Oncology CEO Bruno Strigini to Retire
07:25aDJALNYLAM PHARMACEUTICALS : Stock Rises as FDA Lifts Study Hold
12:05a Wall Street falls as investors fret about tax bill passage
More sector news : Generic Pharmaceuticals
Income Statement Evolution
Consensus
 
Mean consensus BUY
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 123%
EPS Revisions
Managers
NameTitle
Horst G. Zerbe Chairman, President & Chief Executive Officer
André Godin Chief Financial Officer & Executive Vice President
Nadine Paiement Director-Research & Development
Bernd Josef Melchers Independent Director
John Archibald Troup Independent Director